Immupharma Share Discussion Threads

[rathean] 10/9/2018 15:40

As much as I dislike validating the short position, I sold out in two tranches at 21p and 19p booking a loss on this sorry episode. A couple of day trades previously on its bounce to 40p meant the loss is single digit percentage... but still a loss.I had been holding out looking for a positive steer from the bod but the rns was disappointing on many levels and imo puts IMM back into early stage development. The rns also hinted at a fund raise if you read beyond the denial, and the related party deal suggests the bod are looking at escape routes should a white Knight not appear for Lupizor.I'll keep this on my watchlist but the bull case will have to be compelling before I buy these shares again. Gla and dyor ofc :)

[optrade] 10/9/2018 14:53

lse posters have had contact suggest you visit there fast going a lot higher when they drop the rns

[1retirement] 10/9/2018 13:52

Pardon? You haven't articulated the point you may have been trying to make.

[kop202] 10/9/2018 13:30

That maybe...but that doesn't excuse the flagrant rampingchw indulged in in the run up to the Phase 3 results

[kop202] 10/9/2018 12:35

NY...Yes but where are you putting your money

[ny boy] 10/9/2018 12:25

Costax..smart money moving into (IDP) - (7 trading days before results)!

[costax1654x] 10/9/2018 12:18

From 120-150!

[cockerspaniel] 10/9/2018 11:46

Sicilian:
Yes,the die was cast long before Tim became involved.

There remain some serious questions to be asked about the design of the phase III and the SPA, which was done by Cephalon (Immupharma only found out about it afterwards).

Cephalon appear, with hindsigt, to have put as little resources into the development of Lupuzor as possible, and agreed the absolute bare minimum trial - i.e. one which would work only if Lupuzor performed exceptionlly well.

Immupharma's management, however, seem to have represented things differently.
That is hardly unusual in biotech, as founders and management are notoriously over-optimistic.

So, what has Tim done:essentially he got the share price up, raised money from some private investors at a high price - the previous placings being done at a much lower level and were taken by serious investors (not mentioning any names).

The unfortunate private investors may view the situation differently.

Nothing that Tim or Dimitri do happens without the agreement of Robert Zimmer, who has been the driving force behind the company well before it came to the London market (sorry Richard and Dimitri),

Now, what about Nobby?
He has his own agenda - management change at Immupharma and a role for himself.
That's not going to happen by silly postings on bulletin boards, but Nobby is nothing if not persistent.

What about Immupharma?
Hard to say, but looking at it from the perspective of a disappointed shareholder is not going to help. There might be some value for vultures or the cash might end up paying management's not ungenerous salaries for a while longer.

Anyway, a lot has happened in 12 years and most of us (RIP Richard Warr) have lived to tell the tale.

[nobbygnome] 10/9/2018 11:17

>> Col Smith

I suspect half of the patients who went on the OLE got placebo during the actual trial. After all the response rate was almost as good so the optimism is completely misplaced IMHO. I am afraid I look at it the other way, why didn't virtually everyone want to go on the drug. After all it is free and there aren't any side effects.

[1retirement] 10/9/2018 11:16

Coming from someone who ramped the ? out of this not so long ago?!

[costax1654x] 10/9/2018 11:06

Sbtx RNS can land any time.Big rerate coming 34.5 short term.Have a look you won't regret!

[kop202] 10/9/2018 10:14

I got out on the issue of the last underwhelming RNSNo light at the end of the tunnel here....F U ....Tim

[colsmith] 10/9/2018 09:56

The pivot point for this is now the results from early 2019. In a sense we are back to where the company was pre P3 results except there is data now (from P3 tests) on statistical success on a patient sub group and missing end point on the other type of patients. Clearly there is reason for optimism but as ever we only see companies thru dark glasses.

Company optimism I guess is based on the 60 or so people who wanted to continue taking (what was their reason for wanting to continue taking?*) and the intended MAP approach where they believe 500 or so folks will want to take the drug. If they can sell the benefit of taking to the 500 based on I suppose on the 60 ongoing test then it suggests there is a future as the Chair so strongly continues to say.

* did these folks (the 60) get better and so wanted to continue; I can't see why anyone would want to continue taking if they had not got improvement as part of the P3 tests - Intriguing.

An interesting question the company hasn't provided info' on Is why the US group in P3 had such poor results - this is something the company should make clear if indeed thy have determined the reason why non US results where good to very good and US bad.

Have a nice day but looking at the share price is a waste of time, either it will fly in 2019 or not.

[costax1654x] 10/9/2018 09:36

Guys is a dead cat here.Sell and buy SBTX!

[the_fiddler] 10/9/2018 09:26

Everyone is dying to sell in the FIVES now. I told you the MMs locked you in.

[nobbygnome] 10/9/2018 09:19

And going on his past record you cannot be optimistic about the Incanthera deal. Why should we think it will be different this time for a Tim McCarthy company. His record is truly shocking.........

[sicilian_kan] 10/9/2018 09:07

Promotion of the company is a broad enough hat for people to comment on your views.

[nobbygnome] 10/9/2018 09:06

s_k

However, Tim is responsible for misleading shareholders. 'Proven efficacy' with a p value of 0.26.....

I agree he doesn't have a clue about the science....

[sicilian_kan] 10/9/2018 09:01

Tim isn't responsible for the company failing P3. He came on board after the SPA was agreed with the FDA and had no say in the structure of the trials (other than to run them staggered, which ended up in the company's best interests). He is neither the CSO nor the CEO.

However, Tim is responsible for the method of fundraising (use of Lanstead) and for the promotion of the company during P3. The former was very successful despite its many (misdirected) critics at the time. The share price went from 20p to 190p.

The latter, the promotion of the company during P3 is I suspect the nub of where critics might wish to focus their ire on Tim, but some of the criticism here is just ridiculously unfair and misdirected.

I add that:

(1) the scientific strategy now will probably be determined by Zimmer as the CSO and as the largest shareholder. Blame him and get him to respond to concerns if unhappy, not Tim; and

(2) the Incanthera deal I think is a very good one for IMM. They pay no costs, but retain 50% of revenues and get a significant stake in Incanthera.

That said the market cap here is based on Lupuzor's prospects not the nucants.

[datait] 10/9/2018 09:01

Timbrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr

[datait] 10/9/2018 08:56

Stockriser7 Sep '18 - 08:02 - 33297 of 33393
0 3 0
It's a plan, it's progress, it's positive - BUY

AIMHO

GL SR

pmsl

[ny boy] 10/9/2018 08:44

At lease Uncle Tim could be viewed as consistent